58 related articles for article (PubMed ID: 8548752)
21. Human interleukin-2-activated adherent natural killer cells recognize a conserved antigen found on tumor cells and protozoan parasites.
Weisman Z; Evans DL; Jaso-Friedmann L
Nat Immun; 1996-1997; 15(6):269-84. PubMed ID: 9523279
[TBL] [Abstract][Full Text] [Related]
22. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells.
Lee RK; Spielman J; Zhao DY; Olsen KJ; Podack ER
J Immunol; 1996 Sep; 157(5):1919-25. PubMed ID: 8757310
[TBL] [Abstract][Full Text] [Related]
23. Role of LFA-3, ICAM-1, and MHC class I on the sensitivity of human tumor cells to LAK cells.
Gwin JL; Gercel-Taylor C; Taylor DD; Eisenberg B
J Surg Res; 1996 Jan; 60(1):129-36. PubMed ID: 8592403
[TBL] [Abstract][Full Text] [Related]
24. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs.
Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ
J Surg Res; 1998 Oct; 79(2):115-20. PubMed ID: 9758725
[TBL] [Abstract][Full Text] [Related]
25. Follicular lymphoma: in vitro effects of combining lymphokine-activated killer (LAK) cell-induced cytotoxicity and rituximab- and obinutuzumab-dependent cellular cytotoxicity (ADCC) activity.
García-Muñoz R; López-Díaz-de-Cerio A; Feliu J; Panizo A; Giraldo P; Rodríguez-Calvillo M; Grande C; Pena E; Olave M; Panizo C; Inogés S
Immunol Res; 2016 Apr; 64(2):548-57. PubMed ID: 26659089
[TBL] [Abstract][Full Text] [Related]
26. The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid.
Alexander CL; Edward M; MacKie RM
Br J Cancer; 1999 Jul; 80(10):1494-500. PubMed ID: 10408388
[TBL] [Abstract][Full Text] [Related]
27. Protein tyrosine kinase inhibition blocks granule exocytosis and cytolytic function of lymphokine-activated killer cells.
Frederick MJ; Yu TK; Krohn EG; Johnston DA; Grimm EA
Immunopharmacology; 1996 Nov; 35(2):83-102. PubMed ID: 8956972
[TBL] [Abstract][Full Text] [Related]
28. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
29. Lymphokine-activated killer cell susceptibility and multidrug resistance in small cell lung carcinoma.
Savas B; Kerr PE; Ustun H; Cole SP; Pross HF
Anticancer Res; 1998; 18(6A):4355-61. PubMed ID: 9891492
[TBL] [Abstract][Full Text] [Related]
30. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
31. Immune activation by combination human lymphokine-activated killer and dendritic cell therapy.
West EJ; Scott KJ; Jennings VA; Melcher AA
Br J Cancer; 2011 Sep; 105(6):787-95. PubMed ID: 21847125
[TBL] [Abstract][Full Text] [Related]
32. The glycosylation profile of interleukin-2 activated human lymphocytes correlates to their anti-tumor activity.
Voshol H; Dullens HF; Den Otter W; Vliegenthart JF
Anticancer Res; 1996; 16(1):155-9. PubMed ID: 8615602
[TBL] [Abstract][Full Text] [Related]
33. Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity.
Galandrini R; Palmieri G; Piccoli M; Frati L; Santoni A
J Immunol; 1999 Mar; 162(6):3148-52. PubMed ID: 10092764
[TBL] [Abstract][Full Text] [Related]
34. Acidic pH inhibits non-MHC-restricted killer cell functions.
Fischer B; Müller B; Fischer KG; Baur N; Kreutz W
Clin Immunol; 2000 Sep; 96(3):252-63. PubMed ID: 10964544
[TBL] [Abstract][Full Text] [Related]
35. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
36. Infiltration and lysis of tumour cell aggregates by adherent interleukin-2-activated natural killer cells is distinct from specific cytolysis.
Johansson BR; Unger ML; Albertsson P; Casselbrant A; Nannmark U; Hokland M
Nat Immun; 1996-1997; 15(2-3):87-97. PubMed ID: 9162267
[TBL] [Abstract][Full Text] [Related]
37. Kinetic analysis of cytotoxic lymphocyte-target cell interaction as quantified by dual parameter flow cytometry.
Waniewski J; Palucka AK; Porwit A
Cytometry; 1993; 14(4):393-400. PubMed ID: 8513695
[TBL] [Abstract][Full Text] [Related]
38. Generation and partial characterization of melanoma sublines resistant to lymphokine activated killer (LAK) cells. Relevance to doxorubicin resistance.
Rivoltini L; Gambacorti-Passerini C; Supino R; Parmiani G
Int J Cancer; 1989 May; 43(5):880-5. PubMed ID: 2714894
[TBL] [Abstract][Full Text] [Related]
39. The effects of benzo(a)pyrene, nicotine, and tobacco-specific N-nitrosamines on the generation of human lymphokine-activated killer cells.
Lindemann RA; Park NH
Arch Oral Biol; 1989; 34(4):283-7. PubMed ID: 2597022
[TBL] [Abstract][Full Text] [Related]
40. A high molecular weight cytotoxic lymphokine in supernatants of lymphokine-activated killer cells cross-reacts with transforming growth factor beta.
Larisch-Bloch S; Sterman B; Sulitzeanu D
Immunol Lett; 1990 Nov; 26(2):189-92. PubMed ID: 2269489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
